



December 2009

Forward Looking Statements



Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations of Echo Therapeutics (“Echo”), but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to: risks and uncertainties relating to Echo's ability to develop and obtain FDA approval of Durhalieve™, other AzoneTS™ product-candidates or the Symphony™ tCGM System; the availability of substantial additional equity capital to support Echo's research, development and product commercialization activities; and the success of Echo's business, research, development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in Echo's filings with the SEC, including, without limitation, its annual report on Form 10-KSB for the year ended December 31, 2008, its quarterly report on Form 10-Q for the quarter ended September 30, 2009 and its current reports on Form 8-K. Echo disclaims any intent or obligation to update these forward-looking statements. By participating in the following presentation, you agree with Echo to maintain in confidence such information, together with any other non-public information regarding Echo obtained from Echo or their agents during the course of the proposed financing. Echo has caused these materials to be delivered to you in reliance upon such agreement and upon Rule 100(b)(2)(ii) of Regulation FD as promulgated by the SEC.



Company Highlights

- Non-invasive, wireless, continuous blood glucose monitoring system
- Novel platform technology that increases skin permeability
- Two recent licensing transaction validate platform
 - Symphony™ tCGM licensed in South Korea to Handok Pharmaceuticals
 - Prelude™ SkinPrep licensed to Ferndale Pharma for enhanced lidocaine delivery
- Six consecutive positive pilot studies in glucose monitoring conducted to date
- 510-k filing in 1Q10 and approval for Prelude lidocaine 2Q10
 - Revenues in 2Q10
- Pivotal trial and PMA filing anticipated in 2010 for glucose monitoring
- Strategic partnership with Cato Research, a global CRO
- Strong IP portfolio
- Experienced public company management

Symphony tCGM System



Prelude SkinPrep System

- Painlessly removes stratum corneum for accurate measurement of glucose
- Patented feedback control mechanism for optimal skin permeation

Transdermal Glucose Sensor

- Electrochemical glucose sensor plus short-range RF transmitter
- Affixed to area prepared with Prelude

Wireless Remote Monitor

- Accurate readings
- Compatible with ICU software
- Potential use for other devices
- Customizable early-warning alarms for hypo- or hyperglycemia


Ferndale Deal Highlights

- Echo licenses right to develop, market and sell Prelude for enhanced delivery of Ferndale's topical lidocaine product, LMX4, in North America and UK
- Echo receives:
 - \$750k upfront
 - \$750k upon FDA approval
 - \$12.5mn in milestones and guaranteed minimum royalty payments
 - Double digit royalty on net sales of product
 - Ferndale pays all product development expenses for Prelude completion
- Echo will enter into supply agreement with Ferndale for disposable Prelude components
- Total deal value ~\$15mn excluding manufacturing and royalty revenue


Symphony tCGM System Benefits

- Needle-free
- Continuous
 - Readings obtained every 20 seconds
- Wireless data transmission
- Short, one-hour warm-up
- Low manufacturing cost

tCGM Biosensing Process



Symphony™ vs. Competitors



Continuous BG Monitoring System Comparison

Device	Echo Symphony	Abbot Freestyle Navigator	Medtronic Guardian RT	Dexcom SEVEN	MiniMed Paradigm
Target Markets	Critical care Home use	Home use	Home use	Home use	Home use
Needle-free	Yes	No	No	No	No
Sensor Life	24 to 48 hours	120 hours	72 hours	168 hours	72 hours
Initialization Time	~ 1 hour	10 hours	2 hours	2 hours	2 hours
Calibrations Required	TBD	4 (at 10, 12, 24 and 74 hours)	6 (every 12 hours)	14 (every 12 hours)	6 (every 12 hours)
Accuracy	97% to 100%	98.0%	98.9%	97.0%	98.9%
Error Rate (MARD)	7.5% to 16%	NA	19.7%	15.7%	19.7%
Frequency of Reading	1 min	1 min	5 min	5 min	5 min
Cost	Inexpensive	Expensive	Expensive	Expensive	Expensive
Regulatory Status	Clinical trials	Approved	Approved	Approved	Approved


Source: Industry research and websites

Symphony Home Use Pilot Study 1


- Completed in July 2006
- Goal: Evaluate safety and performance of Symphony by comparing needle-free, wireless, real-time blood glucose (BG) monitoring to SOC finger-stick BG monitoring in patients with Type 1 or Type 2 diabetes
- Device: SonoPrep and a first generation glucose biosensor
- Design:
 - 10 patients with Type 1 or Type 2 diabetes enrolled
 - Two sensors placed on each patient
 - Symphony BG measured for 12 hours
 - Symphony data compared to BG measurements from finger-stick blood drawn every hour

Symphony Home Use Pilot Study 1 Data

Symphony ⁽¹⁾ vs. SOC Finger-stick



Clarke Error Grid ⁽¹⁾⁽²⁾



(1) Utilizing ultrasound-mediated skin preparation


(2) Clinical accuracy evaluation

(3) Mean Absolute Relative Difference

Symphony Hospital Critical Care Pilot Study 1

- Completed in December 2006
- Goals: Evaluate safety and performance of Symphony by comparing needle-free, wireless, real-time BG monitoring to SOC finger-stick BG monitoring in intra-operative and intensive care setting
- Device: SonoPrep and a second generation glucose biosensor
- Design:
 - Eight patients undergoing elective cardiac surgery enrolled at Tufts
 - One transdermal biosensor used to collect data for 24 hours, during and after surgery
 - BG measured at least every hour
 - Symphony data compared to BG measurements

Symphony Hospital Critical Care Pilot Study 1 Data




Results: (N = 147)
A+B% in CEG = 100% MARD = 11.2%

Symphony Hospital Critical Care Pilot Study 2

- Completed in March 2008
- Goal: Evaluate safety and performance of Symphony by comparing needle-free, wireless, real-time BG monitoring to SOC finger-stick BG monitoring in intra-operative and intensive care setting
- Device: SonoPrep and the latest generation biosensor technology incorporating proprietary hydrogel chemistry
- Design:
 - 25 patients undergoing elective cardiac surgery enrolled at Tufts
 - Two transdermal biosensors were applied to each subject, one prior to surgery and one after surgery
 - Symphony data compared to reference measurements from blood analyzers, glucometers and lab results based on the Tufts glucose monitoring protocols


Symphony Hospital Critical Care Pilot Study 2 Data



Prelude Feasibility Study

- Completed in April 2008
- Goal: Evaluate the performance of Prelude as part of the Symphony tCGM System
- Device: Prelude SkinPrep System with Symphony biosensor and proprietary hydrogel technology
- Design:
 - Six healthy adult subjects enrolled
 - Skin prepared using the Prelude device
 - One biosensor applied to each patient
 - BG references taken at least every hour for 24 hours


Prelude Feasibility Study Data



MR1 Study

- Completed in July 2008
- Goal: Evaluate performance of Prelude SkinPrep System and Symphony tCGM by comparing needle-free, wireless, real-time BG monitoring to YSI glucose analyzer in an outpatient setting
- Device: Prelude SkinPrep System and the latest generation Symphony biosensor technology incorporating proprietary hydrogel chemistry
- Design:
 - 10 volunteer subjects with confirmed diagnosis of Type I or Type II diabetes
 - Two transdermal biosensors were applied to each subject
 - Continuous blood glucose readings collected by Symphony for up to 24 hours
 - Symphony data compared to reference measurements from YSI glucose analyzer

MR1 Study Data



MR1 Study Data

- Continuous Error Grid Results

	Overall		Hypoglycemia (BG ≤ 70 mg/dL) 2.2% of the data		Euglycemia (70 < BG ≤ 180 mg/dL) 60.1% of the data		Hyperglycemia (BG > 180 mg/dL) 37.7% of the data	
	N	%	N	%	N	%	N	%
Accurate	1182	94.0	24	85.7	733	97.0	425	89.7
Benign	52	4.1	0	0.0	22	2.9	30	6.3
Erroneous	24	1.9	4	14.3	1	0.1	19	4.0
All	1258	100.0	28	100	756	100	474	100

- MARD: 13.8%
- No adverse events, including follow-ups at 24h and 7d after device removal

MR II Study

- Completed in November 2009
- Goal: Evaluate performance of Symphony tCGM by comparing needle-free, wireless, real-time BG monitoring to YSI glucose analyzer in an outpatient setting
- Device: Prelude SkinPrep and the Symphony tCGM incorporating one-piece, single use biosensor technology
- Design:
 - Ten transdermal biosensors were used in evaluation of subjects with confirmed diagnosis of Type I or Type II diabetes
 - Continuous blood glucose readings collected by Symphony for up to 24 hours
 - Symphony data compared to reference measurements from YSI glucose analyzer

MR II Study Data

- Continuous Error Grid Results

	Overall		Hypoglycemia (BG ≤ 70 mg/dL) 2.9% of the data		Euglycemia (70 < BG ≤ 180 mg/dL) 76.8% of the data		Hyperglycemia (BG > 180 mg/dL) 20.2% of the data	
	N	%	N	%	N	%	N	%
Accurate	786	95.9	8	33.9	624	99.0	154	92.8
Benign	9	1.1	0	0.0	6	1.0	3	1.8
Erroneous	25	3.0	16	66.7	0	0.0	9	5.4
All	820	100.0	24	100.0	630	100.0	166	100.0

- MARD: 12.8%
- No adverse events, including follow-ups at 24h and 7d after device removal

Conclusion from Symphony Pilot Studies

- Symphony is effective at monitoring BG
- Symphony data strongly correlate to SOC BG measurements
- Symphony accuracy superior to handheld glucometers
- Hypoglycemia accuracy appears to be most accurate published
- Symphony is reliable with no failures during studies
- No safety concerns identified

Critical Care Market Opportunity

- 6,000 hospitals in US
- 120,000 critical care hospital beds
- 30mn hospital critical care patient days at 70% occupancy
- Hospitals currently spend up to ~\$200/day in tight glycemic control
 - Assumes finger-stick glucose checks every hour
- Critical care market opportunity greater than \$1bn
- Clear benefits to having a needle-free continuous monitor at lower price point as current standard-of-care
- Echo is positioned to be “*first-to-market*” with tCGM in hospital

Symphony Intellectual Property

- Feedback mechanism for optimal skin permeation control
 - 1 US patent, 3 US applications, 4 foreign applications
- Non-invasive, continuous transdermal biosensor
 - 2 US patent, 1 foreign patent, 5 US applications, 12 foreign applications
- Sonophoresis for transdermal drug delivery or diagnosis
 - 5 US patents, 3 foreign patents
- Ultrasound pretreatment followed by drug delivery or diagnosis
 - 4 US patents, 3 foreign patents, 2 US applications

Experienced Team

- Patrick Mooney, MD: Chairman and CEO
 - Chairman, CEO and President, Aphton Corporation
 - Senior Biotechnology Analyst, Thomas Weisel Partners
- Harry Mitchell, CPA: COO and CFO
 - EVP, Finance and CFO, Boston Medical Technologies
 - President and CEO, MedTech Advances
- Keith Krystyniak: Director of Engineering
 - Boston Scientific, Abbott, Allergan
- Wayne Menzie: Director of Technology and Clinical Development
 - Boston Scientific, Boston Medical Technologies
- Key Advisors: Robert Langer, Ph.D., Allen Cato, M.D., Ph.D. Stan Nasraway, M.D., Anthony Furnary, M.D., Gail Kongable, R.N., William Clarke, M.D.

Milestones Next 12 Months

- Complete critical care study with commercial Symphony system
- Complete clinical trial of Prelude with lidocaine
- File 510k for FDA approval of Prelude lidocaine product
- FDA approval of Prelude lidocaine product
- Build internal management team for product launch
 - VP Marketing & Sales, Regional Sales Managers, Reimbursement team
- Begin manufacturing scale-up for validation and product launch
- File PMA with US FDA
- FDA approval of Symphony
- Gain AMEX or Nasdaq listing
- Complete strategic partner licensing deals
- Prepare company for potential acquisition

Company Snapshot

- Ticker: ECTE
- HQ: Boston
- Employees: 12
- Market Capitalization: ~\$40 million
- Shares Outstanding: ~26 million